DCPrime initiates its first clinical study in AML patients

Date: 14/04/2011

Amsterdam, The Netherlands – DCPrime announced today that it initiated a clinical study with its first candidate therapeutic cancer vaccine. This is a major milestone in the development of an off-the-shelf dendritic cell vaccine based on the company’s proprietary DCOne platform. For more information see the DCPrime website.